Supporting Informed Decisions Pegylated Interferon Combined with Ribavirin for Chronic Hepatitis C Virus Infection: An Economic Evaluation

[1]  M. Sherman,et al.  Treating chronic hepatitis C with pegylated interferon alfa‐2a (40 KD) and ribavirin in clinical practice , 2006, Alimentary pharmacology & therapeutics.

[2]  M. T. Smolkin.  Medicare and cost-effectiveness analysis. , 2006, The New England journal of medicine.

[3]  D. Dhumeaux,et al.  Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin. , 2005, Journal of hepatology.

[4]  Colin W Shepard,et al.  Global epidemiology of hepatitis C virus infection. , 2005, The Lancet. Infectious diseases.

[5]  Jennifer A. Roberts,et al.  Cost effectiveness of interferon α or peginterferon α with ribavirin for histologically mild chronic hepatitis C , 2005, Gut.

[6]  P. Ritvo,et al.  Potential cost-effectiveness of a preventive hepatitis C vaccine in high risk and average risk populations in Canada. , 2005, Vaccine.

[7]  D. Coyle,et al.  Economic burden of hepatitis C in Canada and the potential impact of prevention , 2005, The European Journal of Health Economics.

[8]  N. Waugh,et al.  Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation. , 2004, Health technology assessment.

[9]  P. Marcellin,et al.  Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. , 2004, Annals of internal medicine.

[10]  Murray Krahn,et al.  Estimating the Prognosis of Hepatitis C Patients Infected by Transfusion in Canada between 1986 and 1990 , 2004, Medical decision making : an international journal of the Society for Medical Decision Making.

[11]  Jesse Green,et al.  Cost effectiveness of peginterferon alpha-2a plus ribavirin versus interferon alpha-2b plus ribavirin as initial therapy for treatment-naive chronic hepatitis C. , 2004, PharmacoEconomics.

[12]  L. Annemans,et al.  A health economic model to assess the long term effects and cost-effectiveness of PEG IFN alpha-2a in hepatitis C virus infected patients. , 2004, Acta gastro-enterologica Belgica.

[13]  W. Klaskala,et al.  Cost-effectiveness of combination peginterferon alpha-2a and ribavirin compared with interferon alpha-2b and ribavirin in patients with chronic hepatitis C. , 2004, The American journal of gastroenterology.

[14]  M. Weinstein,et al.  Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population. , 2003, JAMA.

[15]  T. Wright,et al.  A comparison in the progression of liver fibrosis in chronic hepatitis C between persistently normal and elevated transaminase. , 2003, Journal of hepatology.

[16]  M. Buti,et al.  A cost‐effectiveness analysis of peginterferon alfa‐2b plus ribavirin for the treatment of naive patients with chronic hepatitis C , 2003, Alimentary pharmacology & therapeutics.

[17]  G. Naglie,et al.  Health-State Utilities and Quality of Life in Hepatitis C Patients , 2003, American Journal of Gastroenterology.

[18]  T. Hügle,et al.  Hepatitis C: Update , 2001, Deutsche medizinische Wochenschrift.

[19]  Hepatitis C: nutrition care Canadian guidelines for health care providers. , 2003, Canadian journal of dietetic practice and research.

[20]  M. Manns,et al.  Cost effectiveness of peginterferon alpha-2b plus ribavirin versus interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C. , 2003, Gut.

[21]  T. Asselah,et al.  Fibrosis and disease progression in hepatitis C , 2002, Hepatology.

[22]  William M. Lee,et al.  Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. , 2002, Gastroenterology.

[23]  Dieter Häussinger,et al.  Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. , 2002, The New England journal of medicine.

[24]  J. Kaldor,et al.  Is severe liver disease a common outcome for people with chronic hepatitisC? , 2002, Journal of gastroenterology and hepatology.

[25]  N. Andrews,et al.  Clinical course of hepatitis C virus during the first decade of infection: cohort study , 2002, BMJ : British Medical Journal.

[26]  R. Levine,et al.  Chronic hepatitis C: Watchful waiting versus immediate antiviral therapy , 2002 .

[27]  C. Gluud,et al.  Ribavirin with or without alpha interferon versus no intervention, placebo or alpha interferon for chronic hepatitis C. , 2002, Cochrane Database of Systematic Reviews.

[28]  Blood-borne pathogens routine surveillance system report. , 2002, Canada communicable disease report = Releve des maladies transmissibles au Canada.

[29]  L. Kjaergard,et al.  Interferon alfa with or without ribavirin for chronic hepatitis C: systematic review of randomised trials , 2001, BMJ : British Medical Journal.

[30]  M. Law,et al.  The cost of hepatitis C and the cost-effectiveness of its prevention. , 2001, Health policy.

[31]  J. Kaldor,et al.  Estimating progression to cirrhosis in chronic hepatitis C virus infection , 2001, Hepatology.

[32]  Kenneth Koury,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .

[33]  A. Giulivi,et al.  Current Status of Hepatitis C in Canada , 2000, Canadian Journal of Public Health.

[34]  S. Zou,et al.  Prediction of hepatitis C burden in Canada. , 2000, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.

[35]  J. Wong,et al.  Cost-effectiveness of 24 or 48 weeks of interferon alpha-2b alone or with ribavirin as initial treatment of chronic hepatitis C. International Hepatitis Interventional Therapy Group. , 2000, The American journal of gastroenterology.

[36]  J. Hoofnagle,et al.  Pathogenesis, Natural History, Treatment, and Prevention of Hepatitis C , 2000, Annals of Internal Medicine.

[37]  Z. Goodman,et al.  Is an “à la carte” combination interferon alfa‐2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C? , 2000, Hepatology.

[38]  Hepatitis C: medical information update. Canadian Liver Foundation. National Hepatitis C Education Program. , 2000, Canadian journal of public health = Revue canadienne de sante publique.

[39]  H J Alter,et al.  Recovery, Persistence, and Sequelae in Hepatitis C Virus Infection: A Perspective on Long-Term Outcome , 2000, Seminars in liver disease.

[40]  E L Murphy,et al.  Prevalence of hepatitis C virus infection in the United States. , 1999, The New England journal of medicine.

[41]  William M. Lee,et al.  Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. , 1998, The New England journal of medicine.

[42]  H. Margolis,et al.  Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease , 1998 .

[43]  A. Sangchan.  Interferon Alfa-2b Alone or in Combination with Ribavin as Intial Treatment for Chronic Hepatitis C , 1998 .

[44]  P. Marcellin,et al.  Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT) , 1998, Lancet.

[45]  J. Emparanza,et al.  [The prevalence of hepatitis C virus infection]. , 1998, Gastroenterologia y hepatologia.

[46]  J B Wong,et al.  Estimates of the Cost-Effectiveness of a Single Course of Interferon-2b in Patients with Histologically Mild Chronic Hepatitis C , 1997, Annals of Internal Medicine.

[47]  P. Bedossa,et al.  Natural history of liver fibrosis progression in patients with chronic hepatitis C , 1997, The Lancet.

[48]  A. Bhalla,et al.  Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. , 1997, Gastroenterology.

[49]  J. Hoofnagle,et al.  Classification of chronic hepatitis: Diagnosis, grading and staging , 1994, Hepatology.

[50]  O. Weiland,et al.  Outcome of acute symptomatic non-A, non-B hepatitis: a 13-year follow-up study of hepatitis C virus markers. , 2008, Liver.

[51]  R. Koretz,et al.  Non-A, Non-B Post-Transfusion Hepatitis: Looking Back in the Second Decade , 1993, Annals of Internal Medicine.

[52]  B. Cesana,et al.  Survival and prognostic factors of cirrhotic patients with ascites: a study of 134 outpatients. , 1993, The American journal of gastroenterology.

[53]  A. Alberti,et al.  Long-term follow-up of non-A, non-B (type C) post-transfusion hepatitis. , 1993, Journal of hepatology.

[54]  K. Ishak,et al.  Long‐term clinical and histopathological follow‐up of chronic posttransfusion hepatitis , 1991, Hepatology.

[55]  H. Blum,et al.  Long-term follow-up of posttransfusion and sporadic chronic hepatitis non-A, non-B and frequency of circulating antibodies to hepatitis C virus (HCV). , 1990, Journal of hepatology.

[56]  Neil Kaplowitz,et al.  Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis , 1981, Hepatology.

[57]  R. Purcell,et al.  NON-A, NON-B POST-TRANSFUSION HEPATITIS , 1977, The Lancet.

[58]  T. Rephann,et al.  Association , 1973, ACM SIGSPATIAL International Workshop on Advances in Geographic Information Systems.